Could an immune booster beat long COVID? small trial begins
NCT ID NCT07108036
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests the safety of a drug called Anktiva (N-803) in 20 adults with Long COVID. Participants get up to two shots and are monitored for side effects and changes in immune cells and quality of life. The goal is to see if the drug is safe enough to study further for this condition.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Anktiva (nogapendekin alfa inbakicept, also called N-803)
- What this could lead to
- If this works, it could point toward a treatment that helps the immune system reset and reduce Long COVID symptoms.
- What could go wrong
- This is a very small, early Phase 2 trial focused on safety, not effectiveness. It may not lead to any symptom improvement, and side effects are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LONG COVID are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of California - San Francisco
RECRUITINGSan Francisco, California, 94110, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Could exercise retrain the heart in long COVID?
- Can brain games and gentle currents lift long COVID brain fog?
- Can brain training zap long COVID brain fog?
- Ear device zaps vagus nerve in bid to quiet long COVID fatigue and brain fog
- Smartphone therapy could ease long COVID's mental toll